Table 2.
Changes in exercise performance during beraprost sodium treatment in patients with pulmonary hypertension
| Variable | Baseline | BPS treatment | p Value |
| Peak workload (W) | 87 (4) | 97 (5) | <0.001 |
| Heart rate (beats/min) | |||
| Rest | 82 (2) | 80 (3) | NS |
| Peak | 147 (4) | 152 (4) | NS |
| SAP (mm Hg) | |||
| Rest | 125 (4) | 124 (4) | NS |
| Peak | 162 (6) | 171 (6) | NS |
| Sao2 (%) | |||
| Rest | 97 (1) | 97 (1) | NS |
| Peak | 92 (1) | 91 (1) | NS |
| Peak Borg score (D/L) | 18/17 | 18/18 | NS |
| Peak V̇o2 (ml/kg/min) | 14.9 (0.7) | 16.8 (0.7) | <0.001 |
| ΔV̇o2/ΔW ratio (ml/kg/min/W) | 6.6 (0.3) | 7.4 (0.3) | <0.01 |
| Oxygen pulse (ml/beat) | 6.0 (0.3) | 6.6 (0.3) | <0.001 |
| Maximum V̇e (l/min) | 49 (3) | 52 (3) | NS |
| V̇e–V̇co2 slope | 42 (2) | 37 (1) | <0.001 |
| Peak RQ | 1.27 (0.03) | 1.26 (0.03) | NS |
Data are mean (SEM).
BPS, beraprost sodium; peak Borg score (D/L), Borg score at peak exercise (dyspnoea/leg fatigue); RQ, respiratory quotient; Sao2, arterial oxygen saturation; SAP, systolic arterial pressure; V̇e, minute ventilation; V̇e–V̇co2 slope, slope of regression line of relation between V̇e and V̇co2; ΔV̇o2/ΔW ratio, V̇o2 increase per unit workload.